{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:01:42Z","timestamp":1791615702340,"version":"4.3.4"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01243","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:30:20Z","timestamp":1594081820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1"],"prefix":"10.3389","volume":"11","author":[{"given":"Andrea","family":"Botticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pomati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Grazia","family":"Zizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (checkmate 017 and checkmate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in ovarian high grade serous carcinoma","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget."},{"key":"B12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum Pathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight."},{"key":"B14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.oraloncology.2014.04.003","article-title":"The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck","volume":"50","author":"Zandberg","year":"2014","journal-title":"Oral Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Network","year":"2015","journal-title":"Nature."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.21037\/tlcr.2018.01.14","article-title":"Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution","volume":"7","author":"Salati","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2019.1631136","article-title":"Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy","volume":"30","author":"Lee","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0167-5699(99)01520-0","article-title":"Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?","volume":"20","author":"Mellor","year":"1999","journal-title":"Immunol Today."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1178646917691938","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"15","author":"Badawy","year":"2017","journal-title":"Int J Tryptophan Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.4049\/jimmunol.164.7.3596","volume":"164","author":"Hwu","year":"2000","journal-title":"J Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25\u2212 into CD25+ T regulatory cells","volume":"109","author":"Curti","year":"2007","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.4049\/jimmunol.181.8.5396","article-title":"The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","article-title":"Indoleamine 2,3-dioxygenaseexpressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells","volume":"114","author":"Chung","year":"2009","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T-cell immunotherapy targeting cTLA4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.imlet.2007.06.001","article-title":"Tumor immune escape mediated by indoleamine 2,3-dioxygenase","volume":"111","author":"Zamanakou","year":"2007","journal-title":"Immunol Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.2147\/OTT.S136259","article-title":"The status of immunosuppression in patients with stage III B or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy","volume":"10","author":"Wang","year":"2017","journal-title":"OncoTargets Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/15384047.2018.1450116","article-title":"Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer","volume":"19","author":"Li","year":"2018","journal-title":"Cancer Biol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/eji.201444522","article-title":"Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion","volume":"44","author":"Zoso","year":"2014","journal-title":"Eur J Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood-2007-10-116111","article-title":"Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells","volume":"111","author":"Lob","year":"2008","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.bbapap.2011.07.023","article-title":"Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors","volume":"1814","author":"Meininger","year":"2011","journal-title":"Biochim Biophys Acta."},{"key":"B37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-018-1595-3","article-title":"Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?","volume":"16","author":"Botticelli","year":"2018","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/JCO.19.00709","article-title":"Lesion-level response dynamics to programmed cell death protein (PD-1) blockade","volume":"37","author":"Osorio","year":"2019","journal-title":"J Clin Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12967-019-1847-x","article-title":"A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab","volume":"17","author":"Botticelli","year":"2019","journal-title":"J Transl Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E203","DOI":"10.3390\/vaccines8020203","article-title":"The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy","volume":"8","author":"Botticelli","year":"2020","journal-title":"Vaccines (Basel)."},{"key":"B41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e981457","DOI":"10.4161\/2162402X.2014.981457","volume":"4","author":"Ferns","year":"2015","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"384726","DOI":"10.1155\/2011\/384726","article-title":"Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma","volume":"2011","author":"Zhang","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.oraloncology.2011.03.007","article-title":"Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas","volume":"47","author":"Laimer","year":"2011","journal-title":"Oral Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12094-017-1657-7","article-title":"Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy","volume":"19","author":"Aparicio","year":"2017","journal-title":"Clin Transl Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"15","author":"Finke","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00432-010-0944-2","article-title":"Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2","volume":"137","author":"Huang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int Rev Cell Mol Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fimmu.2014.00673","article-title":"Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.CIR-15-0095","article-title":"Tumoral immune resistance mediated by enzymes that degrade tryptophan","volume":"3","author":"van Baren","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"JCO2018789602","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2018.36.15_suppl.9512","volume":"36","author":"Zakharia","year":"2018","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:30:21Z","timestamp":1594081821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2020.01243"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01243","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"article-number":"1243"}}